21,416 results match your criteria Rheumatoid Spondylitis


Randomized double-blinded controlled trial on the effect of synbiotic supplementation on IL-17/IL-23 pathwayand disease activity in patients with axial spondyloarthritis.

Immunopharmacol Immunotoxicol 2022 Aug 10:1-24. Epub 2022 Aug 10.

Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Background: interleukin 17 (IL17)-expressing CD4 T cells and IL-17/IL-23 pathway play a key role in the pathogenesis of axial spondyloarthritis (axSpA). Synbiotics have been suggested due to their immunomodulatory effects in the treatment of autoimmune diseases. This randomized double-blind, placebo-controlled trial was designed to assess the effects of synbiotic supplement on IL-17/IL-23 pathway and disease activity in patients with axSpA. Read More

View Article and Full-Text PDF

Clinical Results of Utilizing the Satellite Rod Technique in Treating Ankylosing Spondylitis Kyphosis.

Orthop Surg 2022 Aug 10. Epub 2022 Aug 10.

Department of Orthopaedics, Chinese People's Liberation Army General Hospital (301 Hospital), Beijing, China.

Objective: According to the literature, there are no clinical reports documenting the use of the satellite rod technique in the treatment of ankylosing spondylitis kyphosis. The purpose of this retrospective study was to compare the clinical outcome of patients with ankylosing spondylitis kyphosis who adopted satellite rods versus those who did not.

Methods: Patients with ankylosing spondylitis kyphosis who underwent one or two-level pedicle subtraction osteotomy (PSO) were reviewed, and total of 119 patients (112 males and seven females, average age 39. Read More

View Article and Full-Text PDF

An infected Andersson lesion presented with incomplete paraplegia in a patient with ankylosing spondylitis. A unique case report with literature review.

Spinal Cord Ser Cases 2022 Aug 9;8(1):73. Epub 2022 Aug 9.

Orthopedic Department of General Hospital of Patras Spine and Trauma Unit, Patras, Greece.

Introduction: A relatively rare and unknown entity in patients with ankylosing spondylitis is the Andersson lesion (AL). It was first described by Andersson in 1937 as destructive vertebral or disco-vertebral lesion of the spine without history of trauma. AL may result from inflammation or stress fracture of the rigid spine, while there is no evidence for an infectious origin. Read More

View Article and Full-Text PDF

Predictors of remission in people with axial spondyloarthritis: A systematic literature review.

Semin Arthritis Rheum 2022 Jul 27;56:152078. Epub 2022 Jul 27.

Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom. Electronic address:

Background: Achievement of remission is a desirable outcome and the identification of predictors of remission may aid in the clinical management of axial spondyloarthritis (axSpA). Our aim was to summarise predictors of remission in people with axSpA.

Methods: In this systematic literature review (SLR), we searched MEDLINE, EMBASE, and Cochrane CENTRAL from their inception to May 20, 2022, and 2020-2021 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) meeting abstracts. Read More

View Article and Full-Text PDF

Risk factors for developing Inflammatory Bowel Disease Within and Across Families with Family History of IBD.

J Crohns Colitis 2022 Aug 9. Epub 2022 Aug 9.

Gastrounit, Medical Division, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.

Introduction: A family history of IBD is the strongest risk factor for disease. However, some first-degree relatives (FDRs) will develop disease, while others will not.

Methods: Using the nationwide Danish National Patient Register, we examined risk factors in families with ≥2 affected FDRs. Read More

View Article and Full-Text PDF

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.

Arthritis Res Ther 2022 Aug 8;24(1):187. Epub 2022 Aug 8.

Department of Rheumatology, Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Mexico.

Objective: To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA).

Methods: Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or methotrexate. Patients were randomly assigned 1:1 to the infusion of infliximab 5mg/kg or placebo; completers entered then an open-label extension (OLE) period of 42 weeks. Read More

View Article and Full-Text PDF

Ranking the importance of their own diseases: A positioning analysis in rheumatic patients and their proxies.

Reumatol Clin (Engl Ed) 2022 Aug-Sep;18(7):429-434

Unidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, Mexico; Universidad Autónoma de Guadalajara, Guadalajara, Mexico. Electronic address:

Introduction/objective: To assess the positioning that patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and their proxies give to their diseases.

Methods: Subjects completed a self-administered questionnaire to rank 11 diseases from "worst" to "least bad". Then they defined the "worst" disease and ranked 10 diseases from highest to lowest importance from a list including "my rheumatic disease/my relative's disease". Read More

View Article and Full-Text PDF

World mortality of ankylosing spondylitis, psoriatic arthritis and inflammatory bowel disease in 2015 and its evolution from 2001 to 2015.

Joint Bone Spine 2022 Aug 5:105452. Epub 2022 Aug 5.

Department of Rheumatology, CHRU de Besançon, 3 boulevard Fleming, 25000 Besançon, France; EA 4267 "PEPITE‿, UFR Santé, Franche-Comté University, 19 rue Ambroise Paré, bâtiment S 25030 Besançon cedex, France.

Objective: There is little epidemiological data on global mortality in spondyloarthritis (SpA) and inflammatory bowel disease. We then determined mortality rates of ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn's disease (CD) and ulcerative colitis (UC) both globally and by country, and to describe their evolution between 2001 and 2015.

Methods: We used mortality data from the World Health Organisation (WHO), which shows the number of deaths classified by age, sex, and cause of death coded by ICD-10. Read More

View Article and Full-Text PDF

The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease.

Rheumatol Int 2022 Aug 8. Epub 2022 Aug 8.

Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.

Ankylosing spondylitis (AS) is a seronegative, chronic inflammatory arthritis with high genetic burden. A strong association with HLA-B27 has long been established, but to date its contribution to disease aetiology remains unresolved. Recent insights through genome wide studies reveal an increasing array of immunogenetic risk variants extraneous to the HLA complex in AS cohorts. Read More

View Article and Full-Text PDF

The effects of Pilates training on respiratory muscle strength in patients with ankylosing spondylitis.

Physiother Theory Pract 2022 Aug 8:1-11. Epub 2022 Aug 8.

Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Gazi University, Ankara, Turkey.

Background: Reduction in flexibility and mobility are important factors that lead to impairments in quality of life, reduction of exercise tolerance, and a decreased pulmonary capacity with the progression of Ankylosing Spondylitis (AS).

Aim: The purpose of this study was to investigate the effects of Pilates exercises on mobility, quality of life, and respiratory muscle strength in patients with AS.

Methods: Forty patients with AS were randomly divided into two groups as Pilates group and the control group. Read More

View Article and Full-Text PDF

Efficacy and Safety of Curcumin and Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.

Front Immunol 2022 22;13:891822. Epub 2022 Jul 22.

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.

Background: Modern pharmacological research found that the chemical components of are mainly curcumin and turmeric volatile oil. Several recent randomized controlled trials (RCT) have shown that curcumin improves symptoms and inflammation in patients with arthritis.

Methods: Pubmed, Cochran Library, CNKI, and other databases were searched to collect the randomized controlled trials (RCTs). Read More

View Article and Full-Text PDF

The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19.

Front Pharmacol 2022 22;13:960267. Epub 2022 Jul 22.

Shandong University of Traditional Chinese Medicine, Jinan, China.

Similar pathogenesis makes Corona Virus Disease 2019 (COVID-19) associated with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and gouty arthritis (GA), and it is possible to introduce common drugs for the treatment of RA, AS and GA into the treatment of COVID-19. That is, "homotherapy for heteropathy", especially cytokine inhibitors. But little is known about the specific link between the diseases. Read More

View Article and Full-Text PDF

What is the purpose of the diagnostic criterion for fibromyalgia?

Authors:
Katsuhiro Toda

Rheumatol Int 2022 Aug 6. Epub 2022 Aug 6.

Department of Orthopedic Surgery, Hiroshima Clinic, 4th floor Fuji Ground, 2-1, Takara-machi, Naka-ku, Hiroshima, 730-0044, Japan.

View Article and Full-Text PDF

Development and Validation of a Machine Learning-Based Nomogram for Prediction of Ankylosing Spondylitis.

Rheumatol Ther 2022 Aug 6. Epub 2022 Aug 6.

The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China.

Introduction: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the spine and its affiliated tissues. AS mainly affects the axial bone, sacroiliac joint, hip joint, spinal facet, and adjacent ligaments. We used machine learning (ML) methods to construct diagnostic models based on blood routine examination, liver function test, and kidney function test of patients with AS. Read More

View Article and Full-Text PDF

Microbiota-assisted therapy for systemic inflammatory arthritis: advances and mechanistic insights.

Cell Mol Life Sci 2022 Aug 6;79(9):470. Epub 2022 Aug 6.

State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, China.

Research on the influence of gut microbiota on systemic inflammatory arthritis has exploded in the past decade. Gut microbiota changes may be a crucial regulatory component in systemic inflammatory arthritis. As a result of advancements in the field, microbiota-assisted therapy has evolved, but this discipline is still in its infancy. Read More

View Article and Full-Text PDF

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease.

Intest Res 2022 Aug 8. Epub 2022 Aug 8.

Seoul National University College of Medicine, Seoul, Korea.

Background/aims: Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes. Read More

View Article and Full-Text PDF

A brief human history of ankylosing spondylitis: A scoping review of pathogenesis, diagnosis, and treatment.

Surg Neurol Int 2022 15;13:297. Epub 2022 Jul 15.

Department of Neurosurgery, Mayo Clinic, Phoenix, United States.

Background: Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disease of the spine and SI joints. Diagnostic criteria and treatments have continued to evolve, necessitating a historical compendium of AS and its management. This paper aims to review the historical context underlying the discovery of AS, as well as the major diagnostic and therapeutic discoveries in the last two centuries. Read More

View Article and Full-Text PDF

Letter to the Editor Regarding "Andersson Lesion Occurring in the Lumbosacral Segment of a Young Man: A Case Report and Literature Review".

World Neurosurg 2022 Feb;158:331

Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China. Electronic address:

View Article and Full-Text PDF
February 2022

Sustained improvements in EQ-5D utility scores and self-rated health status in patients with ankylosing spondylitis after spa treatment including low-dose radon - an analysis of prospective radon indication registry data.

BMC Musculoskelet Disord 2022 Aug 3;23(1):743. Epub 2022 Aug 3.

Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria.

Background: Patients with ankylosing spondylitis (AS) have significantly lower quality of life (QoL) than the general population. Holistic interventions addressing QoL comprise spa- or balneotherapy including radon. These interventions have shown to be beneficial in reducing pain and improving QoL in AS-patients. Read More

View Article and Full-Text PDF

Degenerative changes of lumbar spine and their clinical implications in patients with axial spondyloarthritis.

Clin Rheumatol 2022 Aug 3. Epub 2022 Aug 3.

Department of Rheumatology, Gaziosmanpasa Hospital, Istinye University, Istanbul, Turkey.

The objective of this study was to assess degenerative changes (DCs) on magnetic resonance imaging (MRI) of lumbar spine in axial spondyloarthritis (axSpA) and non-specific mechanical low back pain (mLBP). Patients were consecutively recruited and all underwent MRI of the lumbar spine in this cross-sectional study. Disk degeneration (DD, Pfirrmann classification), endplate changes (Modic, types 1, 2, and 3), annular fissure, disk bulging, and protrusion or extrusion at each lumbar spinal level were assessed using anonymized images. Read More

View Article and Full-Text PDF

[Recommendations for diagnosis and treatment of ankylosing spondylitis].

Zhonghua Nei Ke Za Zhi 2022 Aug;61(8):893-900

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.

Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the sacroiliac joints, spine and peripheral joints. In China, standardized diagnosis and treatment of AS is still to be popularized. Based on the evidence and guidelines from China and other countries, Chinese Rheumatology Association developed standardization of diagnosis and treatment of AS. Read More

View Article and Full-Text PDF

Physicians' vs patients' global assessments of disease activity in rheumatology and musculoskeletal trials: A meta-research project with focus on reasons for discrepancies.

Semin Arthritis Rheum 2022 Jul 21;56:152074. Epub 2022 Jul 21.

Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark. Electronic address:

Background: In most rheumatic and musculoskeletal diseases (RMDs), global assessments of disease activity by physicians and patients are 'anchor outcomes' in therapeutic trials evaluating whether a treatment is effective.

Objectives: To compare physicians' vs patients' global assessments of disease activity in RMD trials and explore reasons for discrepancies between them.

Methods: Eligible trials were sampled from systematic reviews of treatments for RMDs by using the Cochrane database of systematic reviews (i. Read More

View Article and Full-Text PDF

Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study.

Rheumatology (Oxford) 2022 Aug 3. Epub 2022 Aug 3.

Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Medical School, Athens, Greece.

Objectives: To investigate Covid-19-associated risk of hospitalization and death in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in comparison with the general population during pandemic's first year and compare their overall mortality with 2019.

Methods: Interlinking nation-wide electronic registries, we recorded confirmed Covid-19-associated infections, hospitalizations and deaths, and all-cause deaths between 1-March-2020 and 28-February-2021 in all adults with RA, AS, PsA, SLE, and SSc under treatment (n = 74 970, median age 67.5, 51. Read More

View Article and Full-Text PDF

Age and Symptoms at Onset of Ankylosing Spondylitis in Japanese Patients.

Mod Rheumatol 2022 Aug 3. Epub 2022 Aug 3.

Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Objective: To examine the age at onset and initial symptoms as clinical features of ankylosing spondylitis (AS) in Japanese patients.

Methods: This retrospective study included 60 Japanese patients diagnosed with AS at our institute between January 2004 and June 2021. Initial symptoms were considered pain in axial joints and/or extra-axial joints. Read More

View Article and Full-Text PDF

Functional significance of the rare rs35667974 gene polymorphism, associated with multiple autoimmune diseases, using a structural biological approach.

Autoimmunity 2022 Aug 2:1-7. Epub 2022 Aug 2.

Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece.

Autoimmune diseases, which affect approximately 5% of human population, are a range of diseases in which the immune response to self-antigens results in damage or dysfunction of tissues. Recent genome wide association studies (GWAS) have successfully identified novel autoimmune disease-associated loci, with many of them shared by multiple disease-associated pathways but much of the genetics and pathophysiological mechanisms remain still obscure. Considering that most of the potential causal variants are still unknown, many studies showed that the missense variant rs35667974 at interferon-induced with helicase C domain 1 () gene is protective for type 1 diabetes (T1D), psoriasis (PS) and psoriatic arthritis (PsA). Read More

View Article and Full-Text PDF

Inflammatory Arthritis Facilitators and Barriers (IFAB) for physical activity questionnaire: cross-cultural adaptation into Turkish and evaluation of its psychometric properties.

Disabil Rehabil 2022 Aug 1:1-8. Epub 2022 Aug 1.

Department of Rheumatology, University of Health Sciences, Haydarpaşa Numune Research and Training Hospital, Istanbul, Turkey.

Purpose: We aimed to conduct the translation and cross-cultural adaptation of the Inflammatory arthritis Facilitators and Barriers (IFAB) questionnaire into Turkish language for patients with axial spondyloarthritis (axSpA) and analyze the psychometric properties of the IFAB-Turkish version (IFAB-Tr).

Methods: Data from ninety-three patients with axSpA were analyzed who completed the IFAB-Tr, Health Assessment Questionnaire (HAQ), Hospital Anxiety and Depression Scale (HADS) and Bath Ankylosing Spondylitis Functional Index (BASFI). Internal consistency, test-retest reliability, convergent validity, floor and ceiling effect, measurement error were examined. Read More

View Article and Full-Text PDF

Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.

Front Immunol 2022 14;13:891328. Epub 2022 Jul 14.

Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, Luzhou, China.

TL1A, also called TNFSF15, is a member of tumor necrosis factor family. It is expressed in different immune cell, such as monocyte, macrophage, dendritic cell, T cell and non-immune cell, for example, synovial fibroblast, endothelial cell. TL1A competitively binds to death receptor 3 or decoy receptor 3, providing stimulatory signal for downstream signaling pathways, and then regulates proliferation, activation, apoptosis of and cytokine, chemokine production in effector cells. Read More

View Article and Full-Text PDF

Ankylosing Spondylitis and the Risk of Lung Cancer: A Meta-Analysis and Mendelian Randomization.

Front Genet 2022 15;13:861984. Epub 2022 Jul 15.

Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China.

It remains uncertain whether ankylosing spondylitis is associated with an increased risk of lung cancer. We conducted a meta-analysis to comprehensively evaluate the correlation between ankylosing spondylitis and lung cancer based on existing literature. Eligible studies were identified by searching the PubMed, Web of Science, Embase, and Cochrane Library before 26 March 2021. Read More

View Article and Full-Text PDF

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet 2022 07;400(10349):369-379

Department of Immunology, AbbVie, North Chicago, IL, USA.

Background: Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Methods: The SELECT-AXIS 2 non-radiographic axial spondyloarthritis study was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 113 sites across 23 countries (Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Israel, Japan, Mexico, Poland, Russia, Slovakia, South Korea, Spain, Taiwan, Turkey, Ukraine, and the USA). Read More

View Article and Full-Text PDF

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis.

Lancet 2022 07;400(10349):340-341

Section of Rheumatology, Boston University School of Medicine, Boston, MA, 02118, USA; VA Boston Healthcare System, Boston, MA, USA. Electronic address:

View Article and Full-Text PDF